M&R Capital Management Inc. Sells 313 Shares of Pfizer Inc. (NYSE:PFE)

M&R Capital Management Inc. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 45,439 shares of the biopharmaceutical company’s stock after selling 313 shares during the quarter. M&R Capital Management Inc.’s holdings in Pfizer were worth $2,328,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Front Street Capital Management Inc. increased its stake in shares of Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares during the period. Lindenwold Advisors increased its stake in shares of Pfizer by 1.0% in the third quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock valued at $926,000 after buying an additional 216 shares during the period. SRS Capital Advisors Inc. increased its stake in shares of Pfizer by 1.6% in the second quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 218 shares during the period. Signet Financial Management LLC increased its stake in shares of Pfizer by 0.6% in the third quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock valued at $1,503,000 after buying an additional 220 shares during the period. Finally, Mitchell Mcleod Pugh & Williams Inc. boosted its position in shares of Pfizer by 0.7% during the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock valued at $1,487,000 after purchasing an additional 222 shares in the last quarter. 67.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. UBS Group set a $45.00 target price on Pfizer in a research report on Tuesday, March 14th. Berenberg Bank set a $40.00 target price on Pfizer in a research report on Tuesday, February 7th. SVB Leerink cut their target price on Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 1st. Atlantic Securities cut their target price on Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 1st. Finally, The Goldman Sachs Group upgraded Pfizer from a “neutral” rating to a “buy” rating and upped their target price for the company from $47.00 to $60.00 in a research report on Tuesday, December 13th. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $50.38.

Pfizer Stock Down 0.7 %

Shares of NYSE:PFE opened at $40.10 on Friday. The firm has a market cap of $225.33 billion, a P/E ratio of 7.32, a PEG ratio of 1.35 and a beta of 0.64. Pfizer Inc. has a 52-week low of $39.23 and a 52-week high of $56.32. The business’s 50 day simple moving average is $43.26 and its two-hundred day simple moving average is $46.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.03 by $0.11. The firm had revenue of $24.30 billion during the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.08 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 3.3 EPS for the current fiscal year.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.